nodes	percent_of_prediction	percent_of_DWPC	metapath
Furosemide—ALB—liver cancer	0.417	1	CbGaD
Furosemide—ABCC2—bile canaliculus—liver cancer	0.0681	0.466	CbGeAlD
Furosemide—ABCC2—Sorafenib—liver cancer	0.057	0.622	CbGbCtD
Furosemide—ABCC2—Doxorubicin—liver cancer	0.0346	0.378	CbGbCtD
Furosemide—ABCC2—bile duct—liver cancer	0.0213	0.146	CbGeAlD
Furosemide—ABCC2—bile—liver cancer	0.0164	0.112	CbGeAlD
Furosemide—CA9—gall bladder—liver cancer	0.00941	0.0644	CbGeAlD
Furosemide—Hypochloraemia—Epirubicin—liver cancer	0.00663	0.0331	CcSEcCtD
Furosemide—Hypochloraemia—Doxorubicin—liver cancer	0.00613	0.0306	CcSEcCtD
Furosemide—Hydronephrosis—Epirubicin—liver cancer	0.00535	0.0267	CcSEcCtD
Furosemide—Hydronephrosis—Doxorubicin—liver cancer	0.00495	0.0247	CcSEcCtD
Furosemide—ALB—gall bladder—liver cancer	0.00484	0.0331	CbGeAlD
Furosemide—CA5A—liver—liver cancer	0.00472	0.0323	CbGeAlD
Furosemide—Tubulointerstitial nephritis—Sorafenib—liver cancer	0.00362	0.0181	CcSEcCtD
Furosemide—CA2—gall bladder—liver cancer	0.00357	0.0245	CbGeAlD
Furosemide—Hypocalcaemia—Sorafenib—liver cancer	0.00303	0.0151	CcSEcCtD
Furosemide—Drug interaction—Sorafenib—liver cancer	0.00299	0.0149	CcSEcCtD
Furosemide—CA14—liver—liver cancer	0.00262	0.0179	CbGeAlD
Furosemide—Bullous eruption—Epirubicin—liver cancer	0.00259	0.013	CcSEcCtD
Furosemide—SLC22A11—liver—liver cancer	0.00242	0.0165	CbGeAlD
Furosemide—Bullous eruption—Doxorubicin—liver cancer	0.0024	0.012	CcSEcCtD
Furosemide—CA2—embryo—liver cancer	0.00227	0.0155	CbGeAlD
Furosemide—SLCO2A1—liver—liver cancer	0.00217	0.0148	CbGeAlD
Furosemide—Dermatitis exfoliative—Sorafenib—liver cancer	0.00213	0.0107	CcSEcCtD
Furosemide—Hyponatraemia—Sorafenib—liver cancer	0.00202	0.0101	CcSEcCtD
Furosemide—PGD—liver—liver cancer	0.00193	0.0132	CbGeAlD
Furosemide—Dehydration—Sorafenib—liver cancer	0.00187	0.00935	CcSEcCtD
Furosemide—Local reaction—Epirubicin—liver cancer	0.00185	0.00925	CcSEcCtD
Furosemide—Hypokalaemia—Sorafenib—liver cancer	0.00183	0.00915	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.00181	0.00906	CcSEcCtD
Furosemide—Local reaction—Doxorubicin—liver cancer	0.00171	0.00856	CcSEcCtD
Furosemide—Pancreatitis—Sorafenib—liver cancer	0.00171	0.00852	CcSEcCtD
Furosemide—Eruption—Epirubicin—liver cancer	0.00167	0.00832	CcSEcCtD
Furosemide—CA1—liver—liver cancer	0.00162	0.0111	CbGeAlD
Furosemide—Hypomagnesaemia—Epirubicin—liver cancer	0.00161	0.00806	CcSEcCtD
Furosemide—Eruption—Doxorubicin—liver cancer	0.00154	0.0077	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00154	0.00768	CcSEcCtD
Furosemide—Renal failure—Sorafenib—liver cancer	0.00153	0.00762	CcSEcCtD
Furosemide—Hypomagnesaemia—Doxorubicin—liver cancer	0.00149	0.00746	CcSEcCtD
Furosemide—Hepatobiliary disease—Sorafenib—liver cancer	0.00147	0.00733	CcSEcCtD
Furosemide—Thrombosis—Epirubicin—liver cancer	0.00145	0.00723	CcSEcCtD
Furosemide—Blister—Epirubicin—liver cancer	0.00142	0.0071	CcSEcCtD
Furosemide—ALB—liver—liver cancer	0.00142	0.00972	CbGeAlD
Furosemide—Urinary tract disorder—Sorafenib—liver cancer	0.00138	0.00687	CcSEcCtD
Furosemide—Urethral disorder—Sorafenib—liver cancer	0.00137	0.00682	CcSEcCtD
Furosemide—Thrombosis—Doxorubicin—liver cancer	0.00134	0.00669	CcSEcCtD
Furosemide—ABCC2—liver—liver cancer	0.00133	0.00911	CbGeAlD
Furosemide—Erythema multiforme—Sorafenib—liver cancer	0.00132	0.00658	CcSEcCtD
Furosemide—Blister—Doxorubicin—liver cancer	0.00132	0.00657	CcSEcCtD
Furosemide—Tinnitus—Sorafenib—liver cancer	0.0013	0.00649	CcSEcCtD
Furosemide—Glycosuria—Epirubicin—liver cancer	0.00127	0.00632	CcSEcCtD
Furosemide—Angiopathy—Sorafenib—liver cancer	0.00126	0.00631	CcSEcCtD
Furosemide—Immune system disorder—Sorafenib—liver cancer	0.00126	0.00628	CcSEcCtD
Furosemide—Injection site pain—Epirubicin—liver cancer	0.00126	0.00627	CcSEcCtD
Furosemide—Arrhythmia—Sorafenib—liver cancer	0.00124	0.00621	CcSEcCtD
Furosemide—Erythema—Sorafenib—liver cancer	0.00121	0.00606	CcSEcCtD
Furosemide—Malnutrition—Sorafenib—liver cancer	0.00121	0.00606	CcSEcCtD
Furosemide—Dysgeusia—Sorafenib—liver cancer	0.00119	0.00593	CcSEcCtD
Furosemide—Glycosuria—Doxorubicin—liver cancer	0.00117	0.00585	CcSEcCtD
Furosemide—Jaundice cholestatic—Epirubicin—liver cancer	0.00117	0.00583	CcSEcCtD
Furosemide—Muscle spasms—Sorafenib—liver cancer	0.00117	0.00582	CcSEcCtD
Furosemide—Injection site pain—Doxorubicin—liver cancer	0.00116	0.0058	CcSEcCtD
Furosemide—Anaemia—Sorafenib—liver cancer	0.00112	0.0056	CcSEcCtD
Furosemide—Hypocalcaemia—Epirubicin—liver cancer	0.00112	0.00559	CcSEcCtD
Furosemide—Hyperuricaemia—Epirubicin—liver cancer	0.0011	0.00552	CcSEcCtD
Furosemide—Leukopenia—Sorafenib—liver cancer	0.00109	0.00542	CcSEcCtD
Furosemide—Jaundice cholestatic—Doxorubicin—liver cancer	0.00108	0.00539	CcSEcCtD
Furosemide—CA2—liver—liver cancer	0.00105	0.00717	CbGeAlD
Furosemide—Blood uric acid increased—Epirubicin—liver cancer	0.00104	0.00521	CcSEcCtD
Furosemide—Hypocalcaemia—Doxorubicin—liver cancer	0.00104	0.00517	CcSEcCtD
Furosemide—SLC22A5—liver—liver cancer	0.00103	0.00705	CbGeAlD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00103	0.00512	CcSEcCtD
Furosemide—Hyperuricaemia—Doxorubicin—liver cancer	0.00102	0.00511	CcSEcCtD
Furosemide—Dry mouth—Sorafenib—liver cancer	0.00101	0.00504	CcSEcCtD
Furosemide—Anaphylactic shock—Sorafenib—liver cancer	0.000989	0.00494	CcSEcCtD
Furosemide—Shock—Sorafenib—liver cancer	0.000973	0.00486	CcSEcCtD
Furosemide—Nervous system disorder—Sorafenib—liver cancer	0.00097	0.00485	CcSEcCtD
Furosemide—Thrombocytopenia—Sorafenib—liver cancer	0.000969	0.00484	CcSEcCtD
Furosemide—Blood uric acid increased—Doxorubicin—liver cancer	0.000966	0.00482	CcSEcCtD
Furosemide—Aplastic anaemia—Epirubicin—liver cancer	0.000962	0.00481	CcSEcCtD
Furosemide—Skin disorder—Sorafenib—liver cancer	0.000961	0.0048	CcSEcCtD
Furosemide—Anorexia—Sorafenib—liver cancer	0.000943	0.00471	CcSEcCtD
Furosemide—Cramps of lower extremities—Epirubicin—liver cancer	0.000942	0.0047	CcSEcCtD
Furosemide—Bladder pain—Epirubicin—liver cancer	0.000927	0.00463	CcSEcCtD
Furosemide—Aplastic anaemia—Doxorubicin—liver cancer	0.00089	0.00445	CcSEcCtD
Furosemide—Mental disability—Epirubicin—liver cancer	0.000889	0.00444	CcSEcCtD
Furosemide—Cramps of lower extremities—Doxorubicin—liver cancer	0.000871	0.00435	CcSEcCtD
Furosemide—Decreased appetite—Sorafenib—liver cancer	0.00086	0.0043	CcSEcCtD
Furosemide—Thrombophlebitis—Epirubicin—liver cancer	0.000859	0.00429	CcSEcCtD
Furosemide—Bladder pain—Doxorubicin—liver cancer	0.000857	0.00428	CcSEcCtD
Furosemide—Diabetes mellitus—Epirubicin—liver cancer	0.000855	0.00427	CcSEcCtD
Furosemide—Gastrointestinal disorder—Sorafenib—liver cancer	0.000854	0.00427	CcSEcCtD
Furosemide—Fatigue—Sorafenib—liver cancer	0.000853	0.00426	CcSEcCtD
Furosemide—Photosensitivity—Epirubicin—liver cancer	0.000847	0.00423	CcSEcCtD
Furosemide—Pain—Sorafenib—liver cancer	0.000846	0.00423	CcSEcCtD
Furosemide—Constipation—Sorafenib—liver cancer	0.000846	0.00423	CcSEcCtD
Furosemide—Vascular purpura—Epirubicin—liver cancer	0.000832	0.00415	CcSEcCtD
Furosemide—Mental disability—Doxorubicin—liver cancer	0.000823	0.00411	CcSEcCtD
Furosemide—Gastrointestinal pain—Sorafenib—liver cancer	0.000809	0.00404	CcSEcCtD
Furosemide—Thrombophlebitis—Doxorubicin—liver cancer	0.000795	0.00397	CcSEcCtD
Furosemide—Diabetes mellitus—Doxorubicin—liver cancer	0.000791	0.00395	CcSEcCtD
Furosemide—Dermatitis exfoliative—Epirubicin—liver cancer	0.000788	0.00394	CcSEcCtD
Furosemide—Urticaria—Sorafenib—liver cancer	0.000786	0.00393	CcSEcCtD
Furosemide—Photosensitivity—Doxorubicin—liver cancer	0.000784	0.00392	CcSEcCtD
Furosemide—Abdominal pain—Sorafenib—liver cancer	0.000782	0.00391	CcSEcCtD
Furosemide—Body temperature increased—Sorafenib—liver cancer	0.000782	0.00391	CcSEcCtD
Furosemide—Dermatitis bullous—Epirubicin—liver cancer	0.000778	0.00389	CcSEcCtD
Furosemide—Purpura—Epirubicin—liver cancer	0.000772	0.00386	CcSEcCtD
Furosemide—Vascular purpura—Doxorubicin—liver cancer	0.00077	0.00384	CcSEcCtD
Furosemide—Anaphylactoid reaction—Epirubicin—liver cancer	0.000769	0.00384	CcSEcCtD
Furosemide—Lethargy—Epirubicin—liver cancer	0.000759	0.00379	CcSEcCtD
Furosemide—Hyponatraemia—Epirubicin—liver cancer	0.000747	0.00373	CcSEcCtD
Furosemide—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00073	0.00364	CcSEcCtD
Furosemide—Hypersensitivity—Sorafenib—liver cancer	0.000729	0.00364	CcSEcCtD
Furosemide—Dermatitis bullous—Doxorubicin—liver cancer	0.00072	0.0036	CcSEcCtD
Furosemide—Purpura—Doxorubicin—liver cancer	0.000714	0.00357	CcSEcCtD
Furosemide—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000711	0.00355	CcSEcCtD
Furosemide—Asthenia—Sorafenib—liver cancer	0.00071	0.00355	CcSEcCtD
Furosemide—Lethargy—Doxorubicin—liver cancer	0.000703	0.00351	CcSEcCtD
Furosemide—Pruritus—Sorafenib—liver cancer	0.0007	0.0035	CcSEcCtD
Furosemide—Blood creatinine increased—Epirubicin—liver cancer	0.000697	0.00348	CcSEcCtD
Furosemide—Dehydration—Epirubicin—liver cancer	0.000692	0.00346	CcSEcCtD
Furosemide—Hyponatraemia—Doxorubicin—liver cancer	0.000691	0.00345	CcSEcCtD
Furosemide—Orthostatic hypotension—Epirubicin—liver cancer	0.00068	0.00339	CcSEcCtD
Furosemide—Hypokalaemia—Epirubicin—liver cancer	0.000677	0.00338	CcSEcCtD
Furosemide—Diarrhoea—Sorafenib—liver cancer	0.000677	0.00338	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00067	0.00335	CcSEcCtD
Furosemide—Muscular weakness—Epirubicin—liver cancer	0.000656	0.00328	CcSEcCtD
Furosemide—Dizziness—Sorafenib—liver cancer	0.000654	0.00327	CcSEcCtD
Furosemide—Abdominal distension—Epirubicin—liver cancer	0.000647	0.00323	CcSEcCtD
Furosemide—Blood creatinine increased—Doxorubicin—liver cancer	0.000645	0.00322	CcSEcCtD
Furosemide—Dehydration—Doxorubicin—liver cancer	0.00064	0.0032	CcSEcCtD
Furosemide—Eosinophilia—Epirubicin—liver cancer	0.000637	0.00318	CcSEcCtD
Furosemide—Pancreatitis—Epirubicin—liver cancer	0.00063	0.00315	CcSEcCtD
Furosemide—Vomiting—Sorafenib—liver cancer	0.000629	0.00314	CcSEcCtD
Furosemide—Orthostatic hypotension—Doxorubicin—liver cancer	0.000629	0.00314	CcSEcCtD
Furosemide—Hypokalaemia—Doxorubicin—liver cancer	0.000627	0.00313	CcSEcCtD
Furosemide—Rash—Sorafenib—liver cancer	0.000624	0.00312	CcSEcCtD
Furosemide—Dermatitis—Sorafenib—liver cancer	0.000623	0.00311	CcSEcCtD
Furosemide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00062	0.0031	CcSEcCtD
Furosemide—Headache—Sorafenib—liver cancer	0.00062	0.0031	CcSEcCtD
Furosemide—Muscular weakness—Doxorubicin—liver cancer	0.000607	0.00303	CcSEcCtD
Furosemide—Abdominal distension—Doxorubicin—liver cancer	0.000599	0.00299	CcSEcCtD
Furosemide—Pollakiuria—Epirubicin—liver cancer	0.000594	0.00297	CcSEcCtD
Furosemide—Eosinophilia—Doxorubicin—liver cancer	0.000589	0.00294	CcSEcCtD
Furosemide—Nausea—Sorafenib—liver cancer	0.000588	0.00294	CcSEcCtD
Furosemide—Photosensitivity reaction—Epirubicin—liver cancer	0.000587	0.00293	CcSEcCtD
Furosemide—Pancreatitis—Doxorubicin—liver cancer	0.000583	0.00291	CcSEcCtD
Furosemide—Hyperglycaemia—Epirubicin—liver cancer	0.00058	0.0029	CcSEcCtD
Furosemide—Drowsiness—Epirubicin—liver cancer	0.000573	0.00286	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000568	0.00284	CcSEcCtD
Furosemide—Renal failure—Epirubicin—liver cancer	0.000564	0.00282	CcSEcCtD
Furosemide—Sweating—Epirubicin—liver cancer	0.00055	0.00275	CcSEcCtD
Furosemide—Pollakiuria—Doxorubicin—liver cancer	0.00055	0.00275	CcSEcCtD
Furosemide—Photosensitivity reaction—Doxorubicin—liver cancer	0.000543	0.00271	CcSEcCtD
Furosemide—Hepatobiliary disease—Epirubicin—liver cancer	0.000542	0.00271	CcSEcCtD
Furosemide—Hyperglycaemia—Doxorubicin—liver cancer	0.000537	0.00268	CcSEcCtD
Furosemide—Agranulocytosis—Epirubicin—liver cancer	0.000535	0.00267	CcSEcCtD
Furosemide—Drowsiness—Doxorubicin—liver cancer	0.000531	0.00265	CcSEcCtD
Furosemide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000526	0.00263	CcSEcCtD
Furosemide—Renal failure—Doxorubicin—liver cancer	0.000521	0.0026	CcSEcCtD
Furosemide—Sweating—Doxorubicin—liver cancer	0.000509	0.00254	CcSEcCtD
Furosemide—Urinary tract disorder—Epirubicin—liver cancer	0.000508	0.00254	CcSEcCtD
Furosemide—Urethral disorder—Epirubicin—liver cancer	0.000505	0.00252	CcSEcCtD
Furosemide—Hepatobiliary disease—Doxorubicin—liver cancer	0.000502	0.00251	CcSEcCtD
Furosemide—Visual impairment—Epirubicin—liver cancer	0.000496	0.00248	CcSEcCtD
Furosemide—Agranulocytosis—Doxorubicin—liver cancer	0.000495	0.00247	CcSEcCtD
Furosemide—Erythema multiforme—Epirubicin—liver cancer	0.000487	0.00243	CcSEcCtD
Furosemide—Eye disorder—Epirubicin—liver cancer	0.000481	0.0024	CcSEcCtD
Furosemide—Tinnitus—Epirubicin—liver cancer	0.00048	0.0024	CcSEcCtD
Furosemide—Urinary tract disorder—Doxorubicin—liver cancer	0.00047	0.00235	CcSEcCtD
Furosemide—Angiopathy—Epirubicin—liver cancer	0.000467	0.00233	CcSEcCtD
Furosemide—Urethral disorder—Doxorubicin—liver cancer	0.000467	0.00233	CcSEcCtD
Furosemide—Immune system disorder—Epirubicin—liver cancer	0.000465	0.00232	CcSEcCtD
Furosemide—Arrhythmia—Epirubicin—liver cancer	0.00046	0.0023	CcSEcCtD
Furosemide—Visual impairment—Doxorubicin—liver cancer	0.000459	0.00229	CcSEcCtD
Furosemide—Erythema multiforme—Doxorubicin—liver cancer	0.00045	0.00225	CcSEcCtD
Furosemide—Malnutrition—Epirubicin—liver cancer	0.000448	0.00224	CcSEcCtD
Furosemide—Erythema—Epirubicin—liver cancer	0.000448	0.00224	CcSEcCtD
Furosemide—Eye disorder—Doxorubicin—liver cancer	0.000445	0.00222	CcSEcCtD
Furosemide—Tinnitus—Doxorubicin—liver cancer	0.000444	0.00222	CcSEcCtD
Furosemide—Flatulence—Epirubicin—liver cancer	0.000442	0.00221	CcSEcCtD
Furosemide—Dysgeusia—Epirubicin—liver cancer	0.000439	0.00219	CcSEcCtD
Furosemide—Angiopathy—Doxorubicin—liver cancer	0.000432	0.00216	CcSEcCtD
Furosemide—Muscle spasms—Epirubicin—liver cancer	0.000431	0.00215	CcSEcCtD
Furosemide—Immune system disorder—Doxorubicin—liver cancer	0.00043	0.00215	CcSEcCtD
Furosemide—Arrhythmia—Doxorubicin—liver cancer	0.000425	0.00213	CcSEcCtD
Furosemide—Vision blurred—Epirubicin—liver cancer	0.000422	0.00211	CcSEcCtD
Furosemide—Malnutrition—Doxorubicin—liver cancer	0.000415	0.00207	CcSEcCtD
Furosemide—Erythema—Doxorubicin—liver cancer	0.000415	0.00207	CcSEcCtD
Furosemide—Anaemia—Epirubicin—liver cancer	0.000414	0.00207	CcSEcCtD
Furosemide—Agitation—Epirubicin—liver cancer	0.000412	0.00206	CcSEcCtD
Furosemide—Flatulence—Doxorubicin—liver cancer	0.000409	0.00204	CcSEcCtD
Furosemide—Dysgeusia—Doxorubicin—liver cancer	0.000406	0.00203	CcSEcCtD
Furosemide—Vertigo—Epirubicin—liver cancer	0.000403	0.00201	CcSEcCtD
Furosemide—Leukopenia—Epirubicin—liver cancer	0.000401	0.002	CcSEcCtD
Furosemide—Muscle spasms—Doxorubicin—liver cancer	0.000399	0.00199	CcSEcCtD
Furosemide—Vision blurred—Doxorubicin—liver cancer	0.000391	0.00195	CcSEcCtD
Furosemide—Anaemia—Doxorubicin—liver cancer	0.000383	0.00191	CcSEcCtD
Furosemide—Agitation—Doxorubicin—liver cancer	0.000381	0.0019	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000379	0.00189	CcSEcCtD
Furosemide—Dry mouth—Epirubicin—liver cancer	0.000373	0.00186	CcSEcCtD
Furosemide—Vertigo—Doxorubicin—liver cancer	0.000372	0.00186	CcSEcCtD
Furosemide—Leukopenia—Doxorubicin—liver cancer	0.000371	0.00185	CcSEcCtD
Furosemide—Confusional state—Epirubicin—liver cancer	0.000369	0.00184	CcSEcCtD
Furosemide—Anaphylactic shock—Epirubicin—liver cancer	0.000366	0.00183	CcSEcCtD
Furosemide—Shock—Epirubicin—liver cancer	0.00036	0.0018	CcSEcCtD
Furosemide—Nervous system disorder—Epirubicin—liver cancer	0.000359	0.00179	CcSEcCtD
Furosemide—Thrombocytopenia—Epirubicin—liver cancer	0.000358	0.00179	CcSEcCtD
Furosemide—Skin disorder—Epirubicin—liver cancer	0.000355	0.00177	CcSEcCtD
Furosemide—Hyperhidrosis—Epirubicin—liver cancer	0.000354	0.00177	CcSEcCtD
Furosemide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000351	0.00175	CcSEcCtD
Furosemide—Anorexia—Epirubicin—liver cancer	0.000349	0.00174	CcSEcCtD
Furosemide—Dry mouth—Doxorubicin—liver cancer	0.000345	0.00172	CcSEcCtD
Furosemide—Hypotension—Epirubicin—liver cancer	0.000342	0.00171	CcSEcCtD
Furosemide—Confusional state—Doxorubicin—liver cancer	0.000341	0.0017	CcSEcCtD
Furosemide—Anaphylactic shock—Doxorubicin—liver cancer	0.000338	0.00169	CcSEcCtD
Furosemide—Shock—Doxorubicin—liver cancer	0.000333	0.00166	CcSEcCtD
Furosemide—Nervous system disorder—Doxorubicin—liver cancer	0.000332	0.00166	CcSEcCtD
Furosemide—Thrombocytopenia—Doxorubicin—liver cancer	0.000331	0.00165	CcSEcCtD
Furosemide—Skin disorder—Doxorubicin—liver cancer	0.000329	0.00164	CcSEcCtD
Furosemide—Paraesthesia—Epirubicin—liver cancer	0.000328	0.00164	CcSEcCtD
Furosemide—Hyperhidrosis—Doxorubicin—liver cancer	0.000327	0.00163	CcSEcCtD
Furosemide—Somnolence—Epirubicin—liver cancer	0.000325	0.00162	CcSEcCtD
Furosemide—Anorexia—Doxorubicin—liver cancer	0.000323	0.00161	CcSEcCtD
Furosemide—Decreased appetite—Epirubicin—liver cancer	0.000318	0.00159	CcSEcCtD
Furosemide—Hypotension—Doxorubicin—liver cancer	0.000316	0.00158	CcSEcCtD
Furosemide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000316	0.00158	CcSEcCtD
Furosemide—Fatigue—Epirubicin—liver cancer	0.000315	0.00157	CcSEcCtD
Furosemide—Constipation—Epirubicin—liver cancer	0.000313	0.00156	CcSEcCtD
Furosemide—Pain—Epirubicin—liver cancer	0.000313	0.00156	CcSEcCtD
Furosemide—Paraesthesia—Doxorubicin—liver cancer	0.000304	0.00152	CcSEcCtD
Furosemide—Feeling abnormal—Epirubicin—liver cancer	0.000301	0.00151	CcSEcCtD
Furosemide—Somnolence—Doxorubicin—liver cancer	0.000301	0.0015	CcSEcCtD
Furosemide—Gastrointestinal pain—Epirubicin—liver cancer	0.000299	0.00149	CcSEcCtD
Furosemide—Decreased appetite—Doxorubicin—liver cancer	0.000294	0.00147	CcSEcCtD
Furosemide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000292	0.00146	CcSEcCtD
Furosemide—Fatigue—Doxorubicin—liver cancer	0.000292	0.00146	CcSEcCtD
Furosemide—Urticaria—Epirubicin—liver cancer	0.000291	0.00145	CcSEcCtD
Furosemide—Pain—Doxorubicin—liver cancer	0.000289	0.00145	CcSEcCtD
Furosemide—Constipation—Doxorubicin—liver cancer	0.000289	0.00145	CcSEcCtD
Furosemide—Abdominal pain—Epirubicin—liver cancer	0.000289	0.00144	CcSEcCtD
Furosemide—Body temperature increased—Epirubicin—liver cancer	0.000289	0.00144	CcSEcCtD
Furosemide—Feeling abnormal—Doxorubicin—liver cancer	0.000279	0.00139	CcSEcCtD
Furosemide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000277	0.00138	CcSEcCtD
Furosemide—Hypersensitivity—Epirubicin—liver cancer	0.000269	0.00135	CcSEcCtD
Furosemide—Urticaria—Doxorubicin—liver cancer	0.000269	0.00134	CcSEcCtD
Furosemide—Body temperature increased—Doxorubicin—liver cancer	0.000267	0.00134	CcSEcCtD
Furosemide—Abdominal pain—Doxorubicin—liver cancer	0.000267	0.00134	CcSEcCtD
Furosemide—Asthenia—Epirubicin—liver cancer	0.000262	0.00131	CcSEcCtD
Furosemide—Pruritus—Epirubicin—liver cancer	0.000259	0.00129	CcSEcCtD
Furosemide—Diarrhoea—Epirubicin—liver cancer	0.00025	0.00125	CcSEcCtD
Furosemide—Hypersensitivity—Doxorubicin—liver cancer	0.000249	0.00125	CcSEcCtD
Furosemide—Asthenia—Doxorubicin—liver cancer	0.000243	0.00121	CcSEcCtD
Furosemide—Dizziness—Epirubicin—liver cancer	0.000242	0.00121	CcSEcCtD
Furosemide—Pruritus—Doxorubicin—liver cancer	0.000239	0.0012	CcSEcCtD
Furosemide—Vomiting—Epirubicin—liver cancer	0.000233	0.00116	CcSEcCtD
Furosemide—Diarrhoea—Doxorubicin—liver cancer	0.000232	0.00116	CcSEcCtD
Furosemide—Rash—Epirubicin—liver cancer	0.000231	0.00115	CcSEcCtD
Furosemide—Dermatitis—Epirubicin—liver cancer	0.00023	0.00115	CcSEcCtD
Furosemide—Headache—Epirubicin—liver cancer	0.000229	0.00114	CcSEcCtD
Furosemide—Dizziness—Doxorubicin—liver cancer	0.000224	0.00112	CcSEcCtD
Furosemide—Nausea—Epirubicin—liver cancer	0.000217	0.00108	CcSEcCtD
Furosemide—Vomiting—Doxorubicin—liver cancer	0.000215	0.00107	CcSEcCtD
Furosemide—Rash—Doxorubicin—liver cancer	0.000213	0.00107	CcSEcCtD
Furosemide—Dermatitis—Doxorubicin—liver cancer	0.000213	0.00106	CcSEcCtD
Furosemide—Headache—Doxorubicin—liver cancer	0.000212	0.00106	CcSEcCtD
Furosemide—Nausea—Doxorubicin—liver cancer	0.000201	0.001	CcSEcCtD
Furosemide—CA4—Metabolism—GOT1—liver cancer	7.07e-05	0.000488	CbGpPWpGaD
Furosemide—ALB—Platelet degranulation—VEGFA—liver cancer	7.05e-05	0.000487	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—TNF—liver cancer	7.05e-05	0.000487	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—HGF—liver cancer	7.04e-05	0.000486	CbGpPWpGaD
Furosemide—ALB—Vitamin B12 Metabolism—IL6—liver cancer	6.99e-05	0.000483	CbGpPWpGaD
Furosemide—CA5B—Metabolism—MTHFR—liver cancer	6.98e-05	0.000482	CbGpPWpGaD
Furosemide—CA7—Metabolism—MTHFR—liver cancer	6.98e-05	0.000482	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—CSF2—liver cancer	6.96e-05	0.000481	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—PPARA—liver cancer	6.94e-05	0.000479	CbGpPWpGaD
Furosemide—CA12—Metabolism—CYP1A1—liver cancer	6.94e-05	0.000479	CbGpPWpGaD
Furosemide—CA2—Metabolism—CYCS—liver cancer	6.91e-05	0.000477	CbGpPWpGaD
Furosemide—CA7—Metabolism—PPARA—liver cancer	6.85e-05	0.000473	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PPARA—liver cancer	6.85e-05	0.000473	CbGpPWpGaD
Furosemide—PGD—Disease—BRAF—liver cancer	6.81e-05	0.00047	CbGpPWpGaD
Furosemide—CA9—Metabolism—PSMA4—liver cancer	6.81e-05	0.00047	CbGpPWpGaD
Furosemide—CA9—Metabolism—PSMD10—liver cancer	6.81e-05	0.00047	CbGpPWpGaD
Furosemide—CA2—Metabolism—GGT1—liver cancer	6.78e-05	0.000468	CbGpPWpGaD
Furosemide—CA2—Metabolism—GOT1—liver cancer	6.78e-05	0.000468	CbGpPWpGaD
Furosemide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—liver cancer	6.71e-05	0.000464	CbGpPWpGaD
Furosemide—CA1—Metabolism—CYCS—liver cancer	6.63e-05	0.000458	CbGpPWpGaD
Furosemide—CA9—Metabolism—GOT2—liver cancer	6.62e-05	0.000457	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—TP53—liver cancer	6.57e-05	0.000454	CbGpPWpGaD
Furosemide—CA1—Metabolism—GOT1—liver cancer	6.5e-05	0.000449	CbGpPWpGaD
Furosemide—CA1—Metabolism—GGT1—liver cancer	6.5e-05	0.000449	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—HMOX1—liver cancer	6.49e-05	0.000448	CbGpPWpGaD
Furosemide—CA12—Metabolism—MTHFR—liver cancer	6.47e-05	0.000447	CbGpPWpGaD
Furosemide—ALB—Platelet degranulation—TGFB1—liver cancer	6.47e-05	0.000447	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CG—liver cancer	6.45e-05	0.000445	CbGpPWpGaD
Furosemide—PGD—Disease—PIK3CD—liver cancer	6.37e-05	0.00044	CbGpPWpGaD
Furosemide—CA4—Metabolism—GSTP1—liver cancer	6.35e-05	0.000439	CbGpPWpGaD
Furosemide—CA12—Metabolism—PPARA—liver cancer	6.35e-05	0.000438	CbGpPWpGaD
Furosemide—PGD—Disease—SERPINE1—liver cancer	6.3e-05	0.000435	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CG—liver cancer	6.29e-05	0.000434	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CG—liver cancer	6.29e-05	0.000434	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—HMOX1—liver cancer	6.28e-05	0.000434	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—PPARA—liver cancer	6.28e-05	0.000434	CbGpPWpGaD
Furosemide—CA4—Metabolism—HMOX1—liver cancer	6.27e-05	0.000433	CbGpPWpGaD
Furosemide—CA14—Metabolism—PPARG—liver cancer	6.23e-05	0.00043	CbGpPWpGaD
Furosemide—CA9—Metabolism—CYP2E1—liver cancer	6.23e-05	0.00043	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—TP53—liver cancer	6.21e-05	0.000429	CbGpPWpGaD
Furosemide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—liver cancer	6.16e-05	0.000426	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SERPINA1—liver cancer	6.16e-05	0.000425	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—ALB—liver cancer	6.12e-05	0.000423	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	6.12e-05	0.000422	CbGpPWpGaD
Furosemide—ALB—Metabolism—UGDH—liver cancer	6.1e-05	0.000421	CbGpPWpGaD
Furosemide—CA2—Metabolism—GSTP1—liver cancer	6.09e-05	0.000421	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PPARG—liver cancer	6.07e-05	0.000419	CbGpPWpGaD
Furosemide—CA6—Metabolism—PPARG—liver cancer	6.07e-05	0.000419	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CG—liver cancer	6.06e-05	0.000419	CbGpPWpGaD
Furosemide—CA9—Cellular responses to stress—IL6—liver cancer	6.01e-05	0.000415	CbGpPWpGaD
Furosemide—CA2—Metabolism—HMOX1—liver cancer	6.01e-05	0.000415	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CG—liver cancer	5.87e-05	0.000405	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CG—liver cancer	5.87e-05	0.000405	CbGpPWpGaD
Furosemide—PGD—Metabolism—PPARG—liver cancer	5.85e-05	0.000404	CbGpPWpGaD
Furosemide—CA1—Metabolism—GSTP1—liver cancer	5.84e-05	0.000403	CbGpPWpGaD
Furosemide—CA4—Metabolism—GSTM1—liver cancer	5.84e-05	0.000403	CbGpPWpGaD
Furosemide—CA9—Metabolism—CYCS—liver cancer	5.82e-05	0.000402	CbGpPWpGaD
Furosemide—CA1—Metabolism—HMOX1—liver cancer	5.76e-05	0.000398	CbGpPWpGaD
Furosemide—ALB—Metabolism—EPT1—liver cancer	5.74e-05	0.000396	CbGpPWpGaD
Furosemide—CA9—Metabolism—GGT1—liver cancer	5.72e-05	0.000395	CbGpPWpGaD
Furosemide—CA9—Metabolism—GOT1—liver cancer	5.72e-05	0.000395	CbGpPWpGaD
Furosemide—ALB—Folate Metabolism—IL6—liver cancer	5.69e-05	0.000393	CbGpPWpGaD
Furosemide—PGD—Disease—RAF1—liver cancer	5.68e-05	0.000392	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CD—liver cancer	5.67e-05	0.000392	CbGpPWpGaD
Furosemide—CA7—Metabolism—PPARG—liver cancer	5.66e-05	0.000391	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PPARG—liver cancer	5.66e-05	0.000391	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—MAPK14—liver cancer	5.64e-05	0.000389	CbGpPWpGaD
Furosemide—CA14—Metabolism—ALB—liver cancer	5.6e-05	0.000387	CbGpPWpGaD
Furosemide—CA2—Metabolism—GSTM1—liver cancer	5.6e-05	0.000387	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—TNF—liver cancer	5.6e-05	0.000387	CbGpPWpGaD
Furosemide—PGD—Disease—MTOR—liver cancer	5.55e-05	0.000383	CbGpPWpGaD
Furosemide—PGD—Disease—PIK3CB—liver cancer	5.55e-05	0.000383	CbGpPWpGaD
Furosemide—CA4—Metabolism—CYP1A1—liver cancer	5.54e-05	0.000382	CbGpPWpGaD
Furosemide—SLC22A11—Transmembrane transport of small molecules—RAF1—liver cancer	5.53e-05	0.000382	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CD—liver cancer	5.53e-05	0.000382	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CD—liver cancer	5.53e-05	0.000382	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—F2—liver cancer	5.46e-05	0.000377	CbGpPWpGaD
Furosemide—CA5A—Metabolism—ALB—liver cancer	5.46e-05	0.000377	CbGpPWpGaD
Furosemide—CA6—Metabolism—ALB—liver cancer	5.46e-05	0.000377	CbGpPWpGaD
Furosemide—ALB—Metabolism—TAT—liver cancer	5.44e-05	0.000375	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CG—liver cancer	5.44e-05	0.000375	CbGpPWpGaD
Furosemide—CA1—Metabolism—GSTM1—liver cancer	5.37e-05	0.000371	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	5.35e-05	0.000369	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CD—liver cancer	5.33e-05	0.000368	CbGpPWpGaD
Furosemide—CA2—Metabolism—CYP1A1—liver cancer	5.31e-05	0.000366	CbGpPWpGaD
Furosemide—PGD—Metabolism—ALB—liver cancer	5.26e-05	0.000363	CbGpPWpGaD
Furosemide—CA12—Metabolism—PPARG—liver cancer	5.25e-05	0.000362	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—PPARA—liver cancer	5.24e-05	0.000362	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	5.23e-05	0.000361	CbGpPWpGaD
Furosemide—PGD—Disease—CDKN1B—liver cancer	5.21e-05	0.00036	CbGpPWpGaD
Furosemide—CA4—Metabolism—MTHFR—liver cancer	5.16e-05	0.000356	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—ALB—liver cancer	5.16e-05	0.000356	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CD—liver cancer	5.16e-05	0.000356	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CD—liver cancer	5.16e-05	0.000356	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTP1—liver cancer	5.13e-05	0.000355	CbGpPWpGaD
Furosemide—CA7—Metabolism—ALB—liver cancer	5.09e-05	0.000352	CbGpPWpGaD
Furosemide—CA5B—Metabolism—ALB—liver cancer	5.09e-05	0.000352	CbGpPWpGaD
Furosemide—CA1—Metabolism—CYP1A1—liver cancer	5.09e-05	0.000351	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—PPARA—liver cancer	5.08e-05	0.000351	CbGpPWpGaD
Furosemide—CA9—Metabolism—HMOX1—liver cancer	5.06e-05	0.00035	CbGpPWpGaD
Furosemide—CA4—Metabolism—PPARA—liver cancer	5.06e-05	0.00035	CbGpPWpGaD
Furosemide—CA2—Metabolism—MTHFR—liver cancer	4.95e-05	0.000342	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CB—liver cancer	4.94e-05	0.000341	CbGpPWpGaD
Furosemide—PGD—Disease—CTNNB1—liver cancer	4.92e-05	0.00034	CbGpPWpGaD
Furosemide—CA2—Metabolism—PPARA—liver cancer	4.85e-05	0.000335	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CB—liver cancer	4.82e-05	0.000333	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CB—liver cancer	4.82e-05	0.000333	CbGpPWpGaD
Furosemide—PGD—Disease—CDKN1A—liver cancer	4.81e-05	0.000332	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CD—liver cancer	4.78e-05	0.00033	CbGpPWpGaD
Furosemide—CA1—Metabolism—MTHFR—liver cancer	4.74e-05	0.000328	CbGpPWpGaD
Furosemide—CA12—Metabolism—ALB—liver cancer	4.72e-05	0.000326	CbGpPWpGaD
Furosemide—CA9—Metabolism—GSTM1—liver cancer	4.72e-05	0.000326	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—ALB—liver cancer	4.67e-05	0.000322	CbGpPWpGaD
Furosemide—SLC22A5—Transmembrane transport of small molecules—RAF1—liver cancer	4.67e-05	0.000322	CbGpPWpGaD
Furosemide—CA1—Metabolism—PPARA—liver cancer	4.65e-05	0.000321	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CB—liver cancer	4.65e-05	0.000321	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	4.6e-05	0.000317	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IFNA1—liver cancer	4.59e-05	0.000317	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	4.55e-05	0.000314	CbGpPWpGaD
Furosemide—ALB—Selenium Micronutrient Network—IL6—liver cancer	4.52e-05	0.000312	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CB—liver cancer	4.5e-05	0.000311	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CB—liver cancer	4.5e-05	0.000311	CbGpPWpGaD
Furosemide—CA9—Metabolism—CYP1A1—liver cancer	4.47e-05	0.000309	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CG—liver cancer	4.34e-05	0.000299	CbGpPWpGaD
Furosemide—PGD—Disease—STAT3—liver cancer	4.29e-05	0.000296	CbGpPWpGaD
Furosemide—SLC22A8—Transmembrane transport of small molecules—RAF1—liver cancer	4.22e-05	0.000291	CbGpPWpGaD
Furosemide—CA4—Metabolism—PPARG—liver cancer	4.18e-05	0.000289	CbGpPWpGaD
Furosemide—CA9—Metabolism—MTHFR—liver cancer	4.17e-05	0.000288	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CB—liver cancer	4.17e-05	0.000288	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CG—liver cancer	4.16e-05	0.000287	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	4.1e-05	0.000283	CbGpPWpGaD
Furosemide—CA9—Metabolism—PPARA—liver cancer	4.09e-05	0.000282	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PRKCE—liver cancer	4.06e-05	0.00028	CbGpPWpGaD
Furosemide—CA2—Metabolism—PPARG—liver cancer	4.01e-05	0.000277	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	4.01e-05	0.000277	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4e-05	0.000276	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CG—liver cancer	3.99e-05	0.000275	CbGpPWpGaD
Furosemide—PGD—Disease—MYC—liver cancer	3.98e-05	0.000275	CbGpPWpGaD
Furosemide—PGD—Disease—TGFB1—liver cancer	3.98e-05	0.000275	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—ALB—liver cancer	3.89e-05	0.000269	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	3.88e-05	0.000268	CbGpPWpGaD
Furosemide—ALB—Hemostasis—ABL1—liver cancer	3.86e-05	0.000267	CbGpPWpGaD
Furosemide—CA1—Metabolism—PPARG—liver cancer	3.85e-05	0.000266	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IGF2—liver cancer	3.84e-05	0.000265	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CD—liver cancer	3.81e-05	0.000263	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	3.77e-05	0.000261	CbGpPWpGaD
Furosemide—CA4—Metabolism—ALB—liver cancer	3.76e-05	0.00026	CbGpPWpGaD
Furosemide—ALB—Metabolism—CPT1B—liver cancer	3.7e-05	0.000255	CbGpPWpGaD
Furosemide—ALB—Metabolism—GLUL—liver cancer	3.7e-05	0.000255	CbGpPWpGaD
Furosemide—PGD—Disease—KRAS—liver cancer	3.68e-05	0.000254	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	3.68e-05	0.000254	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CD—liver cancer	3.65e-05	0.000252	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HGF—liver cancer	3.63e-05	0.000251	CbGpPWpGaD
Furosemide—CA2—Metabolism—ALB—liver cancer	3.61e-05	0.000249	CbGpPWpGaD
Furosemide—ALB—Hemostasis—CSF2—liver cancer	3.59e-05	0.000248	CbGpPWpGaD
Furosemide—ALB—Metabolism—NR1H4—liver cancer	3.56e-05	0.000246	CbGpPWpGaD
Furosemide—SLC22A6—Transmembrane transport of small molecules—RAF1—liver cancer	3.52e-05	0.000243	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA3—liver cancer	3.5e-05	0.000242	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CG—liver cancer	3.5e-05	0.000242	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CD—liver cancer	3.5e-05	0.000242	CbGpPWpGaD
Furosemide—CA1—Metabolism—ALB—liver cancer	3.46e-05	0.000239	CbGpPWpGaD
Furosemide—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	3.41e-05	0.000236	CbGpPWpGaD
Furosemide—PGD—Disease—PIK3CA—liver cancer	3.38e-05	0.000234	CbGpPWpGaD
Furosemide—CA9—Metabolism—PPARG—liver cancer	3.38e-05	0.000233	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	3.37e-05	0.000233	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CB—liver cancer	3.32e-05	0.000229	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA4—liver cancer	3.2e-05	0.000221	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CB—liver cancer	3.19e-05	0.00022	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.13e-05	0.000216	CbGpPWpGaD
Furosemide—PGD—Disease—HRAS—liver cancer	3.13e-05	0.000216	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	3.13e-05	0.000216	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA2—liver cancer	3.12e-05	0.000216	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CD—liver cancer	3.08e-05	0.000213	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CB—liver cancer	3.05e-05	0.000211	CbGpPWpGaD
Furosemide—CA9—Metabolism—ALB—liver cancer	3.04e-05	0.00021	CbGpPWpGaD
Furosemide—CA14—Metabolism—PIK3CA—liver cancer	3.01e-05	0.000208	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTA1—liver cancer	3.01e-05	0.000208	CbGpPWpGaD
Furosemide—PGD—Disease—IL6—liver cancer	3e-05	0.000207	CbGpPWpGaD
Furosemide—ALB—Metabolism—NAT2—liver cancer	2.98e-05	0.000206	CbGpPWpGaD
Furosemide—CA5A—Metabolism—PIK3CA—liver cancer	2.94e-05	0.000203	CbGpPWpGaD
Furosemide—CA6—Metabolism—PIK3CA—liver cancer	2.94e-05	0.000203	CbGpPWpGaD
Furosemide—ALB—Hemostasis—MAPK14—liver cancer	2.91e-05	0.000201	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	2.87e-05	0.000198	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.86e-05	0.000198	CbGpPWpGaD
Furosemide—ALB—Metabolism—ALDOB—liver cancer	2.86e-05	0.000197	CbGpPWpGaD
Furosemide—PGD—Metabolism—PIK3CA—liver cancer	2.83e-05	0.000196	CbGpPWpGaD
Furosemide—ALB—Hemostasis—F2—liver cancer	2.82e-05	0.000194	CbGpPWpGaD
Furosemide—PGD—Disease—AKT1—liver cancer	2.76e-05	0.000191	CbGpPWpGaD
Furosemide—CA7—Metabolism—PIK3CA—liver cancer	2.74e-05	0.000189	CbGpPWpGaD
Furosemide—CA5B—Metabolism—PIK3CA—liver cancer	2.74e-05	0.000189	CbGpPWpGaD
Furosemide—ALB—Metabolism—CRABP1—liver cancer	2.72e-05	0.000188	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	2.72e-05	0.000188	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CG—liver cancer	2.69e-05	0.000186	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CB—liver cancer	2.68e-05	0.000185	CbGpPWpGaD
Furosemide—CA12—Metabolism—PIK3CA—liver cancer	2.54e-05	0.000175	CbGpPWpGaD
Furosemide—CA14—Metabolism—AKT1—liver cancer	2.46e-05	0.00017	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.45e-05	0.000169	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	2.44e-05	0.000169	CbGpPWpGaD
Furosemide—CA6—Metabolism—AKT1—liver cancer	2.4e-05	0.000166	CbGpPWpGaD
Furosemide—CA5A—Metabolism—AKT1—liver cancer	2.4e-05	0.000166	CbGpPWpGaD
Furosemide—ALB—Metabolism—HPGDS—liver cancer	2.38e-05	0.000164	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CD—liver cancer	2.37e-05	0.000164	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.37e-05	0.000164	CbGpPWpGaD
Furosemide—ALB—Hemostasis—SERPINE1—liver cancer	2.34e-05	0.000162	CbGpPWpGaD
Furosemide—PGD—Metabolism—AKT1—liver cancer	2.31e-05	0.00016	CbGpPWpGaD
Furosemide—CA5B—Metabolism—AKT1—liver cancer	2.24e-05	0.000155	CbGpPWpGaD
Furosemide—CA7—Metabolism—AKT1—liver cancer	2.24e-05	0.000155	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.16e-05	0.000149	CbGpPWpGaD
Furosemide—ALB—Metabolism—PSMA4—liver cancer	2.12e-05	0.000147	CbGpPWpGaD
Furosemide—ALB—Metabolism—PSMD10—liver cancer	2.12e-05	0.000147	CbGpPWpGaD
Furosemide—ALB—Hemostasis—RAF1—liver cancer	2.11e-05	0.000146	CbGpPWpGaD
Furosemide—CA12—Metabolism—AKT1—liver cancer	2.07e-05	0.000143	CbGpPWpGaD
Furosemide—ALB—Metabolism—GOT2—liver cancer	2.06e-05	0.000143	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CB—liver cancer	2.06e-05	0.000143	CbGpPWpGaD
Furosemide—CA4—Metabolism—PIK3CA—liver cancer	2.03e-05	0.00014	CbGpPWpGaD
Furosemide—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	1.99e-05	0.000138	CbGpPWpGaD
Furosemide—CA2—Metabolism—PIK3CA—liver cancer	1.94e-05	0.000134	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP2E1—liver cancer	1.94e-05	0.000134	CbGpPWpGaD
Furosemide—ALB—Hemostasis—IL2—liver cancer	1.9e-05	0.000131	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.88e-05	0.00013	CbGpPWpGaD
Furosemide—CA1—Metabolism—PIK3CA—liver cancer	1.86e-05	0.000129	CbGpPWpGaD
Furosemide—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	1.83e-05	0.000126	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYCS—liver cancer	1.82e-05	0.000125	CbGpPWpGaD
Furosemide—ALB—Metabolism—GOT1—liver cancer	1.78e-05	0.000123	CbGpPWpGaD
Furosemide—ALB—Metabolism—GGT1—liver cancer	1.78e-05	0.000123	CbGpPWpGaD
Furosemide—CA4—Metabolism—AKT1—liver cancer	1.65e-05	0.000114	CbGpPWpGaD
Furosemide—CA9—Metabolism—PIK3CA—liver cancer	1.64e-05	0.000113	CbGpPWpGaD
Furosemide—ALB—Hemostasis—VEGFA—liver cancer	1.61e-05	0.000111	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTP1—liver cancer	1.6e-05	0.000111	CbGpPWpGaD
Furosemide—CA2—Metabolism—AKT1—liver cancer	1.59e-05	0.00011	CbGpPWpGaD
Furosemide—ALB—Metabolism—HMOX1—liver cancer	1.58e-05	0.000109	CbGpPWpGaD
Furosemide—CA1—Metabolism—AKT1—liver cancer	1.52e-05	0.000105	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TGFB1—liver cancer	1.48e-05	0.000102	CbGpPWpGaD
Furosemide—ALB—Metabolism—GSTM1—liver cancer	1.47e-05	0.000102	CbGpPWpGaD
Furosemide—ALB—Metabolism—CYP1A1—liver cancer	1.39e-05	9.63e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—KRAS—liver cancer	1.37e-05	9.46e-05	CbGpPWpGaD
Furosemide—CA9—Metabolism—AKT1—liver cancer	1.34e-05	9.23e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—MTHFR—liver cancer	1.3e-05	8.98e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARA—liver cancer	1.28e-05	8.81e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—PIK3CA—liver cancer	1.26e-05	8.69e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—TP53—liver cancer	1.22e-05	8.41e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—HRAS—liver cancer	1.16e-05	8.04e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.15e-05	7.91e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CG—liver cancer	1.09e-05	7.54e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PPARG—liver cancer	1.05e-05	7.28e-05	CbGpPWpGaD
Furosemide—ALB—Hemostasis—AKT1—liver cancer	1.03e-05	7.1e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CD—liver cancer	9.6e-06	6.63e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CB—liver cancer	8.37e-06	5.78e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—PIK3CA—liver cancer	5.1e-06	3.52e-05	CbGpPWpGaD
Furosemide—ALB—Metabolism—AKT1—liver cancer	4.17e-06	2.88e-05	CbGpPWpGaD
